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Introduction
Doxorubicin (dox, adriamycin) is an anthracycline drug that is 
one of the most effective and widely used anticancer agents for 
the treatment of both hematologic and solid tumors.1 Several 
mechanisms for the chemotherapeutic actions of doxorubicin 
have been proposed, including: (a) intercalation into DNA, lead-
ing to inhibition of macromolecular synthesis; (b) generation of 
reactive oxygen species (ROS), leading to DNA damage or lipid 
peroxidation; and (c) inhibition of topoisomerase II, followed 
by DNA damage. Doxorubicin-mediated apoptotic cell death 
is likely a response to one or more of these upstream actions.1-3 
The clinical efficacy of doxorubicin is limited by both acute and 
chronic complications. Patients receiving doxorubicin frequently 
present with acute side effects such as fatigue, nausea/vomiting, 
pain, sleep disturbances, cachexia and depression.4 In addition, 
patients may develop cardiomyopathy, leading to life-threatening 
congestive heart failure. Cardiomyopathy frequently correlates 
with the total amount of administered drug.3 Production of oxy-
gen radicals has been proposed for doxorubicin-mediated cardio-
toxicity, whereas the inhibition of both topoisomerase enzyme 
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and DNA synthesis is thought to underlie doxorubicin-induced 
death of tumor cells.3,5 Identifying the mechanism(s) by which 
normal and healthy cells respond differentially to doxorubicin 
may present opportunities to decrease the toxicity of doxorubicin 
on normal tissues while maintaining the efficacy of doxorubicin 
as an anti-cancer drug.
The stress-activated protein kinases (SAPKs), p38 mitogen-
activated protein kinase (p38 MAPK) and Jun N-terminal 
kinase (JNK), are frequently activated by a number of cancer 
chemotherapeutics.4 When phosphorylated, the SAPKs initiate 
a cascade that leads to the production of proinflammatory cyto-
kines. Doxorubicin is known to induce the activation of SAPKs 
in a number of normal cell types, including hepatocytes,6 pri-
mary mouse macrophages7 and cardiomyocytes.8,9 Inhibitors 
of p38 MAPK and JNK have been employed to determine 
whether activation of SAPKs contributes either to the efficacy 
or to the undesirable side effects of doxorubicin. Inhibitors of 
p38 MAPK have been effective in blocking apoptosis of cardio-
myocytes following treatment by doxorubicin or daunorubicin, 
a related anthracycline.8,9 Inhibitors of p38 MAPK reduce the 
proinflammatory actions of doxorubicin in macrophages but 
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of ZAK suppressed the doxorubicin-induced cleavage of both 
PARP and caspase-3 in HaCaT cells (Fig. 1a).
To investigate the effects of knockdown of ZAK on 
 doxorubicin-mediated cell death by morphological criteria, we 
analyzed HaCaT cells after staining with a nuclear fluorescent 
dye, bisbenzimide (Fig. 1B). Cells transfected with either scram-
bled (Fig. 1B, i) or ZAK-specific (Fig. 1B, ii) siRNA, but not 
treated with doxorubicin, demonstrated similar morphological 
features with the majority of the cells displaying uniform nuclear 
staining. A minority population in both groups displayed spon-
taneous apoptosis, manifested by brightly-fluorescent pyknotic 
or karyorrhetic nuclei (Fig. 1B, i and ii, arrowheads). We attri-
bute these basal levels of apoptosis to the 24 hrs serum-depri-
vation. HaCaT cells transfected with scrambled siRNA and 
treated with doxorubicin (25 µM for 24 hrs) displayed extensive 
post-apoptotic secondary necrosis, characterized by massive loss 
of normal cellular and nuclear morphology, decreased cellular 
chromatin content and the appearance of ring-like chromatin 
aggregates adjacent to the plasma membrane/cell borders (Fig. 
1B, iii, arrows). Extracellular release of chromatin was evident in 
some areas as localized, pericellular increase of background fluo-
rescence (not shown). In contrast, cells transfected with ZAK-
specific siRNA and treated with doxorubicin (25 µM for 24 hrs) 
displayed markedly preserved normal cellular and nuclear mor-
phologies (Fig. 1B, iv).
To ensure that the ZAK siRNA did not produce off-target 
effects, we employed an additional sequence of siRNA directed 
against the 5' portion of ZAK mRNA (Fig. 1c). SiRNA-
mediated knockdown of ZAK using sequence #2 also sup-
pressed the doxorubicin-induced phosphorylation of JNK and 
p38 MAPK. Additionally, siRNA-mediated knockdown of ZAK 
using sequence #2 suppressed the doxorubicin-induced cleavage 
of PARP, although not as effectively as sequence #1. For this rea-
son, we employed sequence #1 in subsequent experiments.
Doxorubicin-induced inhibition of protein translation mea-
sured by incorporation of [3h]-leucine. An invariant feature of 
ribotoxic stressors is their ability to inhibit protein translation.15 
To determine if doxorubicin inhibits protein synthesis, we exposed 
HaCaT cells to doxorubicin (1 to 25 µM) for varying times (6, 
12 or 24 h), at which times cells were exposed to [3H]-leucine for 
30 min. Exposure to doxorubicin at concentrations of 2.5 µM or 
greater resulted in a progressive decrease in the incorporation of 
[3H]-leucine (Fig. 1B). Cells treated with 2.5 µM doxorubicin 
decreased incorporation of [3H]-leucine to approximately 35% 
by the end of 24 h; treatment with 10 and 25 µM reduced levels 
of [3H]-leucine incorporation to below 10% at 24 h. Continuous 
examination of cells by microscopy demonstrated insignificant 
cell detachment, even 24 h after addition of doxorubicin.
emetine blocks mapK activation after a high dose of doxo-
rubicin. Transduction by ribotoxic stressors of signals that lead 
to activation of SAPKs requires that the ribosomes be involved 
in protein synthesis at the time that cells are exposed to the 
stressor.15 Blockade of protein synthesis by fast-acting inhibi-
tors such as emetine, prior to the exposure of cells to ribotoxic 
stressors, prevents transduction of the signal(s) that lead to acti-
vation of JNK and p38 MAPK. Iordanov, et al. demonstrated 
do not reduce the anti-proliferative actions of doxorubicin in a 
cancer cell line.7
The intercalation of doxorubicin into DNA is thought to 
 comprise a major mode of action in producing cell death. In addi-
tion to its effects on DNA, doxorubicin also causes RNA damage10 
and inhibits the synthesis of DNA, RNA and proteins.11-14 Some 
inhibitors of protein synthesis, known as ribotoxic stressors, acti-
vate SAPKs.15 Well-known ribotoxic stressors include anisomycin, 
blasticidin, ricin, Shiga toxin, sarcin and ultra-violet radiation.15,16 
Here we demonstrate that doxorubicin effectively inhibits protein 
synthesis, activates JNK and p38 MAPK, and causes apoptosis.
Ribotoxic stressors share a common mechanism in that they 
require ZAK, an upstream MAP3K, to activate the pro-apoptotic 
and proinflammatory signaling pathways that lie downstream of 
p38 MAPK and JNK.17,18 SiRNA-mediated knockdown of ZAK 
or administration of a small molecule inhibitor (DHP-2) of ZAK, 
suppress anisomycin- and UV-induced apoptosis and the phos-
phorylation of p38 MAPK and JNK.17 Inhibition of ZAK also 
suppresses Shiga toxin- and ricin-induced SAPK activation and 
improves cell viability.18 By employing siRNA mediated knock-
down of ZAK or administration of sorafenib and nilotinib, kinase 
inhibitors that have a high affinity for ZAK, we provide evidence 
that ZAK is required for doxorubicin-induced proinflammatory 
and apoptotic responses in HaCaT cells, a pseudo-normal human 
keratinocyte cell line, but not in HeLa cells.
Results
Doxorubicin-induced mapK activation and apoptosis are 
decreased after sirNa-mediated knockdown of ZaK. Ribotoxic 
stressors are characterized by their ability to activate JNK and 
p38 MAPK through inhibition of protein synthesis.15 In many 
cell types, ZAK, a MAP3K, is required for ribotoxic stressors to 
be capable of activating the MAPKs, through which these kinases 
modulate the transcription of downstream genes.17,18 In order to 
determine whether doxorubicin activates JNK and p38 MAPK, 
we exposed HaCaT cells to varying concentrations of doxorubi-
cin and detected the increased phosphorylation of JNK and p38 
MAPK by immunoblotting against an antibody specific for the 
phosphorylated form of JNK and p38 MAPK. Phosphorylation 
of these MAPKs was detected 24 h after addition of doxorubicin 
(5 to 50 µM; Fig. 1a). To determine whether ZAK is required 
for doxorubicin to induce the phosphorylation of JNK and p38 
MAPK, we employed siRNA directed against the 5' portion of 
ZAK mRNA. SiRNA-mediated knockdown of ZAK strongly 
suppressed the phosphorylation of JNK and p38 MAPK, deter-
mined in cells that were harvested 24 h after the addition of 
doxorubicin (Fig. 1a). Interestingly, the knockdown of ZAK 
decreased the basal phosphorylation of p38 MAPK (Fig. 1a).
Similar to other cancer chemotherapeutic agents, doxorubicin 
induces apoptosis both in vivo19-22 and in vitro.2,8,9 To determine 
whether the pro-apoptotic effects of doxorubicin are regulated 
through activation of ZAK, we examined the cleavage of poly 
(ADP-ribose) polymerase (PARP) (from 116 kDa to 89 kDa) and 
caspase-3 (from procaspase to p20/p19 and p17 subunits), which 
are frequently employed as indicators of apoptosis. Knockdown 
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mechanisms. In contrast to doxorubicin, the phosphorylation of 
JNK and p38 MAPK was not suppressed by emetine (Fig. 2c).
inhibitors of ZaK block doxorubicin-induced apoptosis 
and mapK activation in hacaT cells. An important goal in 
cancer chemotherapy is to reduce collateral damage in normal 
tissues and organs. The administration of effective doses of doxo-
rubicin to cancer patients is frequently limited by the potential 
for development of cardiotoxicity and other adverse responses.3 
Identification of agents that could selectively suppress the destruc-
tion of normal tissue by doxorubicin may permit the administra-
tion of larger or more frequent doses of doxorubicin to cancer 
patients. Previous studies have demonstrated that inhibition of 
ZAK by an experimental small molecule inhibitor (DHP-2; Eli 
Lilly) reduces ribotoxic stressor-induced cell death.17,18 However, 
that emetine blocked protein synthesis in less than 1 minute after 
the addition to cells.15 To determine whether prior treatment of 
HaCaT cells with emetine would block the activation of JNK 
and p38 MAPK, cells were exposed to emetine or vehicle prior to 
the addition of doxorubicin. We employed a high concentration 
of doxorubicin (0.5 mM) to induce the rapid phosphorylation of 
JNK and p38 MAPK. Doxorubicin induced the phosphorylation 
of JNK and p38 MAPK at 2 h, but not at 1 h or earlier (Fig. 2a). 
Addition of emetine prior to the exposure to doxorubicin com-
pletely blocked the phosphorylation of JNK and p38 MAPK (Fig. 
2a). Doxorubicin suppressed the incorporation of [3H]-leucine 
by 50% at 1 h and completely at 2 h. We performed a similar 
experiment using CdCl
2
, which is not a ribotoxic stressor23 and 
leads to the activation of JNK and p38 MAPK through other 
Figure 1. Effect of ZAK knockdown on doxorubicin-induced apoptosis, activation of SAPKs, and inhibition of protein synthesis. (A) HaCaT cells were 
exposed to ZAK-specific siRNA (zak) or scrambled siRNA (scr) prior to treatment for 24 h with vehicle or doxorubicin (5, 25 or 50 µM), as described in 
Materials and Methods. Lysates were collected and subjected to SDS-PAGE followed by western blot analysis with the antibodies indicated. (B) HaCaT 
cells grown on glass coverslips were exposed to scrambled siRNA (i and iii) or ZAK-specific siRNA (ii and iv) prior to treatment for 24 h with vehicle (i 
and ii) or 25 µM doxorubicin (iii and iv). Cells were exposed to bisbenzimide to examine fluorescent nuclear staining as described in Materials and 
Methods. (C) HaCaT cells were exposed to scrambled siRNA (scr) or ZAK-specific siRNA (zak) sequence #1 from (A) or sequence #2 prior to treatment 
for 24 h with vehicle or 25 µM doxorubicin, as described in Materials and Methods. Lysates were collected and subjected to SDS-PAGE followed by 
western blot analysis with the antibodies indicated. (D) HaCaT cells were treated in triplicate for 6, 12 or 24 hours with either vehicle or 1, 2.5, 10 or 25 
µM of doxorubicin. Cells were pulse-labeled with [3H]-leucine for the final 30 minutes of treatment.
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carcinoma, patients who received sorafenib and doxorubicin 
together had significantly longer median durations of overall 
survival and progression-free survival than patients receiving 
doxorubicin alone.25 Another small molecule kinase inhibitor 
with a high binding affinity for ZAK is nilotinib (Novartis, K
d
 
= 3 nM), which also inhibits breakpoint cluster region-abelson 
(BCR-ABL) and is currently in clinical use for treatment of 
chronic myelogenous leukemia.26 Although the binding affini-
ties of sorafenib and nilotinib for ZAK have been reported, 
neither agent has been tested for their ability to inhibit ZAK 
activity.
To determine whether sorafenib or nilotinib would inhibit 
downstream actions of ZAK, we administered these agents (1 
µM) to HaCaT cells 30 min prior to treatment with doxorubi-
cin (10 µM or 25 µM) for 24 h. The presence of either inhibi-
tor strongly suppressed doxorubicin-induced phosphorylation 
of JNK and p38 MAPK (Fig. 3a). Just as in HaCaT cells 
exposed to ZAK siRNA, exposure of these cells to sorafenib or 
nilotinib decreased the basal phosphorylation of p38 MAPK 
(Fig. 3a). Sorafenib and nilotinib also reduced the cleavage 
of PARP and caspase-3, suggesting that doxorubicin-mediated 
apoptosis was also suppressed.
ZaK inhibitors block daunorubicin-induced apoptosis 
and mapK activation in hacaT cells. Daunorubicin is an 
anthracycline that is considered to act by similar mechanisms 
as doxorubicin but shows less potent antitumor activity.3 To 
determine whether the inhibition of ZAK effects daunorubi-
cin-induced apoptosis and MAPK activation, we pretreated 
HaCaT cells with sorafenib or nilotinib (1 µM) followed 
by daunorubicin (2.5, 10, 25 µM) for 24 h. Similar to the 
experiments with doxorubicin, the presence of either inhibitor 
strongly suppressed daunorubicin-induced phosphorylation of 
JNK and p38 MAPK (Fig. 3B). Sorafenib and nilotinib also 
reduced the cleavage of PARP and caspase-3, suggesting that 
daunorubicin-mediated apoptosis was also suppressed.
inhibitors of JNK or p38 partially block doxorubicin-
induced apoptosis in hacaT cells. ZAK is a MAP3K that has 
been shown to induce the phosphorylation of p38 MAPK and 
JNK. To determine whether suppression of JNK or p38 MAPK 
would inhibit doxorubicin-induced apoptosis, we administered 
SB 203580 (10 µM), SP 600125 (20 µM), or both in com-
bination to HaCaT cells 30 min prior to treatment with 25 
µM doxorubicin for 24 h. The presence of either inhibitor or a 
combination of both resulted in diminished cleavage of PARP 
and caspase-3, suggesting that JNK and p38-MAPK partici-
pated to an extent in doxorubicin-mediated apoptosis. In the 
presence of a pancaspase inhibitor, zVAD-fmk, doxorubicin-
induced apoptosis was completely inhibited (Fig. 3c).
ZaK inhibitors and ZaK sirNa do not block doxorubicin-
induced apoptosis in hela cells. To test whether ZAK inhibitors 
would reduce cell death in a cancerous cell line we pretreated 
HeLa cells with sorafenib or nilotinib (1 µM) followed by doxo-
rubicin (10 µM or 25 µM) for 24 h. In contrast to their ability to 
suppress PARP and caspase-3 cleavage in HaCaT cells, sorafenib 
and nilotinib failed to reduce PARP or caspase-3 cleavage in HeLa 
cells (Fig. 4a). In HeLa cells, doxorubicin failed to increase the 
DHP-2 is no longer produced by Eli Lilly and is unavailable. In a 
comprehensive effort to identify the target of 38 small molecule 
kinase inhibitors, Karaman et al. determined the dissociation 
constants of a panel of 287 distinct protein kinases, including 
ZAK.24 Sorafenib (Bayer), a multi-kinase inhibitor that has been 
employed in the treatment of renal cell carcinoma and hepatocel-
lular carcinoma, was found to have a very high binding affin-
ity for ZAK (K
d
 = 6.3 nM).24 In one trial for hepatocellular 
Figure 2. Inhibition of doxorubicin-induced activation of SAPKs by pre-
treatment with emetine. (A) HaCaT cells were pretreated with vehicle (ii) or 
emetine (100 µg/mL; i and iii) for 30 minutes prior to stimulation with dox-
orubicin (0.5 mM; ii and iii) for 15, 30, 60 or 120 min. Lysates were collected 
and submitted to SDS-PAGE, followed by western blot analysis with the 
antibodies as indicated. (B) HaCaT cells were treated in triplicate for 1, 2, 
3 or 4 hours with vehicle or 0.5 mM doxorubicin. Cells were pulse-labeled 
with [3H]-leucine for the final 30 minutes of treatment. (C) HaCaT cells were 
pretreated with vehicle (ii) or emetine (100 µg/mL; i and iii) for 30 minutes 
prior to stimulation as indicated with CdCl2 (100 µM; ii and iii) for 15, 30, 60 
or 120 min. Lysates were collected and subjected to SDS-PAGE, followed 
by western blot analysis with the antibodies as indicated.
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phosphorylation of JNK and p38 MAPK, perhaps because 
the basal levels of these phosphorylated SAPKs were 
already elevated in the absence of an inducer. Nevertheless, 
the phosphorylation of SAPKs was suppressed by sorafenib 
and nilotinib, suggesting that the inhibitors were capable 
of suppressing ZAK in these cells. These data suggest that 
the elevated endogenous activity of ZAK in HeLa cells may 
be responsible for the increased basal phosphorylation of 
JNK and p38 MAPK.
To test whether ZAK siRNA would reduce doxorubi-
cin-mediated apoptosis in HeLa cells, we employed ZAK-
targeting siRNA. SiRNA-mediated knockdown of ZAK 
slightly reduced doxorubicin-mediated cleavage of PARP 
and caspase-3 in HeLa cells (Fig. 4B), indicating that the 
pro-apoptotic actions of doxorubicin in these cells was 
mediated in part through activation of ZAK.
Doxorubicin-induced alterations of ZaK protein. ZAK 
has two different isoforms, ZAK-α and ZAK-β. ZAK-α 
has an apparent molecular weight of 91 kDa. ZAK-β is a 
shorter species of ZAK (51 kDa) because it lacks several 
exons in the coding region and, compared to ZAK-α, has 
a distinct C-terminus.18 When HaCaT or HeLa cells were 
treated with doxorubicin and immunoblotted for ZAK, 
we noticed that the ZAK-α band decreased in intensity 
(Figs. 1a and 4B). In addition, bands of slightly higher 
molecular weight appeared above the 51 kDa ZAK-β band 
(Figs. 1a* and 4B*).
To determine the kinetics of the disappearance of the 
ZAK-α band and the appearance of slightly higher molec-
ular weight bands above ZAK-β, we added 25 µM of doxo-
rubicin to HaCaT cells and harvested at 4-hour intervals 
up to 24 hours for immunoblotting with ZAK Ab. The 
higher molecular weight bands above ZAK-β appeared 8 
hours after doxorubicin treatment and increased in inten-
sity thereafter. The disappearance of the 91 kDa ZAK-α 
began 16 hours after doxorubicin treatment (Fig. 5a).
To determine if the doxorubicin-induced disappear-
ance of the ZAK-α band and the appearance of the 
higher molecular weight bands above ZAK-β were due 
to phosphorylation, we exposed lysates to calf intestinal 
phosphatase (CIP). The presence of CIP did not alter the 
disappearance or appearance of the ZAK bands, indicat-
ing that neither was a result of phosphorylation (data not 
shown). Immunoblotting with phospho-p38 confirmed 
the efficacy of the phosphatase treatment (data not shown).
To determine if the doxorubicin-induced changes 
in the two ZAK isoforms could result from ubiquitin-
mediated proteolysis, we utilized MG-132, an inhibitor 
of proteasomal degradation. The presence of the MG-132 
compound did not affect the disappearance of the 91 kDa 
ZAK-α band, suggesting that its disappearance was not 
proteasome dependent (Fig. 5B). By contrast, the higher 
molecular weigh bands above ZAK-β increased in intensity 
in the presence of the MG-132 compound, suggesting that 
these bands undergo proteasome-mediated degradation 
after doxorubicin treatment.
Figure 3. Effect of inhibitors on doxorubicin- and daunorubicin-induced 
apoptosis and activation of SAPKs. HaCaT cells were pretreated for 30 
minutes with vehicle or inhibitors. Twelve hours later an additional dose of 
inhibitor was added to each well. Twenty-four hours after the addition of 
doxorubicin or daunorubicin, lysates were collected and subjected to SDS-
PAGE followed by western blot analysis with the antibodies as indicated. (A) 
HaCaT cells were pretreated with vehicle (C), sorafenib (S; 1 µM), or nilotinib 
(N; 1 µM) for 30 minutes, followed by treatment with doxorubicin (10 or 
25 µM) for 24 h. (B) HaCaT cells were pretreated with vehicle (C), sorafenib 
(S; 1 µM), or nilotinib (N; 1 µM) for 30 minutes, followed by treatment with 
daunorubicin (2.5, 10 or 25 µM) for 24 h. (C) HaCaT cells were pretreated with 
vehicle (C), SB 203580 (SB; 10 µM), SP 600125 (SP; 20 µM), both (SB SP), or 
zVAD-fmk (Z; 25 µM) for 30 minutes, followed by treatment with doxorubicin 
(25 µM) for 24 h.
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To determine if the multi-kinase inhibitors, sorafenib and 
nilotinib, could prevent the doxorubicin-induced changes in 
ZAK, we pretreated HaCaT cells with sorafenib or nilotinib 
(1 µM) followed by doxorubicin (10 or 25 µM) for 24 h. The 
presence of either inhibitor prevented both the disappearance of 
ZAK-α and the appearance of the higher molecular weight bands 
above ZAK-β, suggesting that the degradation of ZAK-α and 
the appearance of higher molecular weight bands above ZAK-β 
are coupled to the activation of ZAK (Fig. 5c). To determine 
whether suppressing the phosphorylation of JNK or p38 MAPK 
would inhibit doxorubicin-induced degradation or modification 
of the ZAK isoforms, we administered SB 203580 (10 µM), SP 
600125 (20 µM), or a combination of the two to HaCaT cells 30 
min prior to treatment with 25 µM doxorubicin for 24 h. The 
presence of either inhibitor or a combination of both did not pre-
vent the disappearance of ZAK-α or the appearance of the higher 
molecular weight bands albove ZAK-β (Fig. 5D), suggesting that 
the ZAK-mediated activation of JNK or p38 MAPK did not act 
retrogradely to cause the disappearance of ZAK-α or the appear-
ance of the higher molecular weight bands above ZAK-β.
Discussion
In an effort to identify initial cellular targets of stressors, we 
uncovered a novel stress signaling pathway termed “ribotoxic 
stress”, which results from the inhibition of protein synthesis 
due to interaction of the translational apparatus with disparate 
compounds such as antibiotics (anisomycin, blasticidin S, goug-
erotin), toxins (ricin, Shiga toxin, sarcin, palytoxin, tricothecene 
mycotoxins) and ultraviolet radiation. Transduction of signals 
that lead to activation of SAPKs occurs immediately upon expo-
sure to these stressors and requires that the ribosome be actively 
engaged in protein synthesis at the time of exposure.15,16,23,27,28
Employing siRNA knockdown and chemical inhibition of 
ZAK, a MAP3K, Jandhyala et al. demonstrated that ZAK was 
required for ricin and Shiga toxin to mediate the activation of 
SAPKs and proinflammatory gene expression.18 ZAK is one of 7 
known mixed lineage kinases (MLKs) whose actions have been 
shown to mediate the activation of JNK and p38 MAPK.29 An 
earlier study had demonstrated that siRNA-mediated knockdown 
of ZAK suppressed the activation of JNK and p38 MAPK by 
anisomycin and ultraviolet radiation, two other ribotoxic stress-
ors.17 Taken together, these studies suggest that ZAK uniquely 
communicates signals between ribosomes and the SAPKs.
Figure 4. Effect of ZAK knockdown, sorafenib or nilotinib on doxo-
rubicin-induced apoptosis in HeLa cells. Following exposure to 10 or 
25 µM doxorubicin, HeLa cell lysates were collected and subjected 
to SDS-PAGE, followed by western blot analysis with the antibodies 
as indicated. (A) Cells were pretreated with vehicle (C), sorafenib (S; 1 
µM), or nilotinib (N; 1 µM) for 30 minutes, followed by treatment with 
doxorubicin for 24 h. At 12 h an additional dose of vehicle or inhibitors 
was added to each well. (B) Cells were exposed to scrambled siRNA (scr) 
or ZAK-specific siRNA (zak) as described in Materials and Methods, fol-
lowed by treatment for 24 h with vehicle or doxorubicin.
Figure 5. Effect of inhibition of ZAK, p38 MAPK or JNK on doxorubicin-
induced degradation or modification of ZAK. (A) HaCaT cells were 
exposed to 25 µM doxorubicin and were harvested at 4 h intervals. Ly-
sates were subjected to SDS-PAGE, followed by western blot analysis 
with the antibodies as indicated. (B) HaCaT cells were exposed to 25 
µM doxorubicin. Eight hours later, 5 µM MG-132 or vehicle was added 
to the corresponding wells. Treatment continued for an additional 12 
hours, at which time cells were harvested. Lysates were subjected to 
SDS-PAGE, followed by western blot analysis with the antibodies as 
indicated. (C) Western blot analysis with ZAK antibody on cell lysates 
from Figure 3A. (D) Western blot analysis with ZAK antibody on cell 
lysates from Figure 3C.
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Inhibitors of p38 MAPK have been effective in blocking 
apoptosis of cardiomyocytes following treatment by doxorubicin 
or daunorubicin.8,9 Inhibitors of p38 MAPK reduce the proin-
flammatory actions of doxorubicin in macrophages but do not 
reduce the anti-proliferative actions of doxorubicin in a cancer 
cell line.7 Employing inhibitors of p38 MAPK, JNK or ZAK 
we have asked whether activation of SAPKs would contribute 
to the doxorubicin-induced inflammation and apoptosis of non-
tumor cells. Our findings that siRNA-mediated knockdown of 
ZAK suppressed the doxorubicin-induced apoptosis in HaCaT 
cells, as  demonstrated by the reduction in cleavage of PARP and 
caspase-3 (Fig. 1a), is consistent with the role of ZAK acting 
through JNK and p38 MAPK to induce apoptotic death.
Previous studies have demonstrated that inhibition of ZAK 
by an experimental small molecule inhibitor (DHP-2; Eli Lilly) 
reduces ribotoxic stressor-induced cell death.17,18 To further dem-
onstrate the role of ZAK in doxorubicin-induced apoptosis of 
normal cells we employed two multi-kinase inhibitors with high 
affinity for ZAK, sorafenib (Bayer, K
d
 = 6.3 nM) and nilotinib 
(Novartis, K
d
 = 3 nM).24,26 Nilotinib was developed as a second-
generation inhibitor of BCR-ABL and has been successful in 
treating chronic myelogenous leukemia (CML) in patients that 
have developed resistance to imatinib (Gleevec). Nilotinib’s bind-
ing affinity for ZAK is higher than its affinity for BCR-ABL.40-42 
Neither of these inhibitors had been tested for their ability to block 
ZAK activity in vitro. We demonstrated that sorafenib and nilo-
tinib were each as effective as siRNA-mediated ZAK knockdown 
(Fig. 3), suggesting that these inhibitors can suppress the signaling 
pathway initiated by ZAK. In HaCaT cells, a pseudo-normal cell 
line derived from keratinocytes, sorafenib and nilotinib blocked 
doxorubicin- and duanorubicin-induced apoptosis and the phos-
phorylation of SAPKs (Fig. 3a and B). The suppression of JNK 
or p38-MAPK by the kinase inhibitors SP 600125 and/or SB 
203580 showed partial protection against doxorubicin-induced 
apoptosis. However, the inhibition of apoptosis by these inhibitors 
was not as complete as sorafenib or nilotinib (Fig. 3c).
HeLa cells were more sensitive than HaCaT cells to the pro-
apoptotic effects of doxorubicin. In contrast to the results in 
HaCaT cells, both sorafenib and nilotinib were unable to block 
doxorubicin-induced apoptosis in HeLa cells (Fig. 4a). We con-
firmed the role of ZAK in cytotoxicity following doxorubicin 
treatment by employing siRNA knockdown of ZAK (Fig. 4B). 
The inability of ZAK inhibition to suppress the pro-apoptotic 
actions of doxorubicin in HeLa cells, in contrast to HaCaT cells, 
suggests that pathways other than ZAK may play a role in cyto-
toxicity, in these cells, after doxorubicin treatment. The differ-
ential sensitivity of normal and cancer cells to the pro-apoptotic 
actions of doxorubicin suggest that inhibitors of ZAK may be 
effective in protection of normal cells against the cytotoxic activi-
ties of doxorubicin. However, this possibility must await further 
studies in an animal model.
ZAK has two different isoforms, ZAK-α (91 kDa) and 
ZAK-β (51 kDa). The two isoforms have identical protein kinase 
domains, including the ATP binding site, and separate func-
tions for the two have not been defined.18 HaCaT or HeLa cells 
treated with doxorubicin and immunoblotted for ZAK displayed 
The intercalation of doxorubicin and daunorubicin into DNA 
could comprise a major mode of anthracycline-induced cell death 
induced by these chemotherapeutics. Because doxorubicin also 
causes RNA damage10 and inhibits DNA and RNA synthesis,11,12 
it is not unexpected that doxorubicin would also inhibit the syn-
thesis of proteins.13,14 In addition to inhibition of protein transla-
tion, doxorubicin induces the activation of SAPKs in a number of 
normal cell types, including hepatocytes,6 primary mouse macro-
phages7 and cardiomyocytes.8,9 Our work presented here demon-
strates that doxorubicin inhibits protein synthesis (Fig. 1B) and 
activates SAPKs (Fig. 1a), which suggests that doxorubicin, may 
act as a ribotoxic stressor and transmit signals through activation 
of ZAK.
We have employed clinically relevant doses of doxorubicin, 
ranging from 1–10 µM. HaCaT cells exposed to doxorubicin 
concentrations that are 2.5 µM or greater resulted in a progressive 
decrease in the incorporation of [3H]-leucine over 24 h, suggest-
ing that doxorubicin causes inhibition of translation (Fig. 1B). 
Cells treated with higher concentrations (10 and 25 µM) of doxo-
rubicin responded with decreased levels of [3H]-leucine incorpo-
ration to less than 10%, 24 h later. Doxorubicin also induced the 
phosphorylation of p38 MAPK and JNK when examined 24 h 
after addition of 5 to 50 µM doxorubicin. Knockdown of ZAK 
with siRNA abrogated the doxorubicin-induced phosphoryla-
tion of JNK and p38 MAPK (Fig. 1a), suggesting that ZAK was 
required for doxorubicin-induced activation of SAPKs. Taken 
together, these results demonstrated that doxorubicin behaves as 
a characteristic ribotoxic stressor by activating p38 MAPK and 
JNK through the upstream activation of ZAK.
SAPKs and NFκB participate together in the increased 
expression of proinflammatory cytokines.30-35 Patients under-
going cancer chemotherapy display many of the classic symp-
toms of sickness behavior caused by the increased expression of 
cytokines, including IL-1β, TNFα and IL-6. Some of the acute 
side effects that accompany administration of chemotherapeu-
tics include fatigue, nausea/vomiting, pain, sleep disturbances, 
cachexia and depression.4 A life-threatening adverse reaction to 
doxorubicin treatment is cardiotoxicity, which is a serious limit-
ing factor in the clinical use of doxorubicin.3 Preclinical studies 
indicate that inflammatory responses may be involved in doxo-
rubicin-induced apoptosis of cardiomyocytes.36 For example, 
treatment with soluble Fas, an inhibitor of Fas/Fas ligand inter-
action that can lead to apoptosis, prevents doxorubicin-induced 
cardiotoxicity and concurrently attenuates the inflammation in 
cardiomyocytes.37
Pretreatment with statins can attenuate doxorubicin-induced 
cardiotoxicity via anti-inflammatory effects.38 Olson et al. 
reported a novel anthracycline analog, DIDOX, which was struc-
turally modified from doxorubicin. DIDOX inhibits the produc-
tion of the pro-inflammatory cytokines, TNFα and IL-2. Studies 
in animal models show that, compared to doxorubicin, DIDOX 
inhibits inflammation and reduces cardiotoxicity.39 Identification 
of agents that could selectively suppress the doxorubicin-induced 
inflammation in heart and other organs may prevent the death of 
non-tumor cells permitting the administration of larger doses of 
doxorubicin to cancer patients.
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was performed, at 50 nM siRNA per well using DharmaFECT 
4 (Dharmacon, Lafayette, CO) according to the manufacturer’s 
instructions. After 72 h (HaCaT) or 48 h (HeLa), complete 
medium was removed and the cells were serum deprived for 1 h 
prior to addition of doxorubicin or vehicle (deionized water) for 
24 h, at the indicated doses, prior to the harvest of cell lysates. 
Cell lysates were subjected to immunoblotting.
Fluorescent nuclear staining. HaCaT cells were plated on 
coverslips and exposed to siRNA for 72 hours as previously 
described, followed by exposure to 25 µM doxorubicin or vehicle 
(deionized water) for 24 h. Cells were fixed in 100% methanol 
for 5 min at 4°C and exposed to 10 µg/mL bisbenzimide. Images 
were captured by a Leica DFC350 FX camera attached to a Leica 
DM IRE2 microscope.
measurement of protein synthesis via [3h]-leucine incorpo-
ration. HaCaT cells were grown in 12-well tissue culture plates. 
Treatments were performed in leucine-free/serum-free DMEM, 
for the indicated times and doses of doxorubicin. For the final 30 
minutes of doxorubicin exposure prior to harvesting, cells were 
pulse-labeled with 1 µCi [3H]-leucine in 1 ml DMEM. Ten per-
cent trichloroacetic acid was added to terminate incorporation. 
Following thorough rinsing with water, 88% formic acid was 
added to solubilize the trichloroacetic acid-insoluble proteins and 
the samples were counted in a liquid scintillation counter. In each 
experiment, three wells were used per experimental point.
immunoblotting. Equal numbers of HaCaT or HeLa cells 
were plated, serum deprived for 30 minutes, treated, and lysed 
in 2XESB lysis buffer in preparation for immunoblotting. Equal 
volumes of the cell lysates were separated on a 10% or 13% (for 
caspase-3 antibody) denaturing polyacrylamide gel in the pres-
ence of sodium dodecyl sulfate and were transferred onto polyvi-
nylidene difluoride membranes according to standard laboratory 
procedures. Membranes were incubated with the indicated anti-
bodies and the corresponding horseradish peroxidase-conjugated 
secondary antibodies; signals were detected by using enhanced 
chemiluminescence.
experiments with emetine. HaCaT cells were serum deprived 
and then pretreated for 0.5 h with 100 µg/ml emetine or vehi-
cle (DMSO), followed by treatment with 0.5 mM doxorubicin, 
100 µM CdCl
2
, or vehicle (deionized water) for the indicated 
times. Cells were harvested at various times and subjected to 
immunoblotting.
Treatment with inhibitors. Serum-deprived HaCaT or HeLa 
cells were pretreated for 0.5 hours with sorafenib (1 µM), nilo-
tinib (1 µM), SB 203580 (10 µM), SP 600125 (20 µM), zVAD-
fmk (25 µM) or vehicle (DMSO). At 12 h an additional dose of 
equal amount was added to each well. Cells were treated with the 
indicated doses of doxorubicin (10 or 25 µM), daunorubicin (2.5, 
10 or 25 µM), or vehicle (deionized water) for 24 h, harvested, 
and subjected to immunoblotting.
Doxorubicin time course. HaCaT cells were serum deprived 
and treated with 25 µM doxorubicin or vehicle (deionized water) 
in four-hour increments from 4–24 h. Cell lysates were subjected 
to immunoblotting.
Treatment with mG-132, a proteosome inhibitor. HaCaT 
cells were serum deprived and treated with 25 µM of doxorubicin 
a progressive decrease in the ZAK-α band and the appearance 
of higher molecular weight bands above ZAK-β (Figs. 1a and 
4B). Abrogation of these changes after exposure of the cells to 
sorafenib and nilotinib suggests that these changes occur fol-
lowing stimulation of ZAK by upstream signaling pathways. 
Degradation of ZAK following its activation suggests a homeo-
static mechanism to suppress the continued activation of SAPKs 
by ZAK. Pretreatment of cells with the p38 MAPK inhibitor SB 
203580, the JNK inhibitor SP 600125, or a combination of the 
two failed to prevent the doxorubicin-induced protein changes in 
ZAK, suggesting that activation of p38 MAPK or JNK are not 
involved in targeting ZAK for degradation.
We utilized MG-132, an inhibitor of proteasomal degrada-
tion, to determine if the doxorubicin-induced alterations in the 
two ZAK isoforms could result from ubiquitin-mediated prote-
olysis. The disappearance of the 91 kDa ZAK-α band was not 
prevented by the presence of MG-132, suggesting that it was not 
proteasome dependent. By contrast, the higher molecular weight 
bands above ZAK-β accumulated in the presence of the MG-132 
compound, suggesting that these bands may represent ubiquit-
inylated forms of ZAK-β.
Sorafenib and nilotinib are in clinical use and exhibit very few 
side effects in patients. We suggest that these inhibitors could 
be employed in combination with doxorubicin to treat cancer 
patients because our data suggests that sorafenib or nilotinib 
might be able to reduce doxorubicin-induced apoptosis and SAPK 
phosphorylation in normal tissues. However, it is unknown if the 
presence of sorafenib or nilotinib in combination with doxoru-
bicin could effect the antitumor activity of doxorubicin. Further 
experiments in animal models would determine the efficacy of 
treatment with doxorubicin and either sorafenib or nilotinib.
Materials and Methods
antibodies and other reagents. Antibodies against the phospho-
rylated forms of ERK, JNK, p38 and against active caspase-3 
were purchased from Cell Signaling Technology (Danvers, MA). 
Antibodies against PARP (H-250), JNK1 (FL), and p38 were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Doxorubicin, daunorubicin, bisbenzimide, CdCl
2
, and emetine 
were purchased from Sigma (St. Louis, MO). SB 203580, SP 
600125, MG-132 and zVAD-fmk were purchased from EMD 
Chemicals (Gibbstown, NJ). Scrambled siRNA oligonucle-
otides (sequence: CAA CAC GGA CAU CAU ACG ATT), 
ZAK siRNA oligonucleotides (sequence from Wang et al.17), and 
ZAK#2 siRNA oligonucleotides (sequence: UGU UCA ACU 
CCU AAC UGC GTT) were synthesized by the Research Core 
Facility at Oregon Health & Science University, Portland, OR. 
Sorafenib and nilotinib were purchased from LC Laboratories 
(Woburn, MA). [3H]-leucine was purchased from PerkinElmer 
(Waltham, MA). ZAK antibody was kindly provided by Cheleste 
M. Thorpe (Tufts-New England Medical Center).
sirNa knockdown of ZaK. HaCaT or HeLa cells were 
grown to 70% confluency and treated in Dulbecco modi-
fied Eagle medium/10% FBS. ZAK or scrambled (scr) control 
siRNA were transfected, after titration of siRNA concentration 
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